Literature DB >> 7066186

Experimental cyclosporin A nephrotoxicity.

P H Whiting, A W Thomson, J T Blair, J G Simpson.   

Abstract

The nephrotoxic property of cyclosporin A (Cy A) was investigated in groups of Sprague-Dawley rats given various dose regimes over a 21-day period. Impairment of glomerular filtration was clearly evidenced by elevated serum urea and creatinine levels and by reduced urea clearance rates. There were also dose-related increases in urinary N-acetyl-beta-D-glucosaminidase activity. These biochemical changes were accompanied by structural evidence of damage to the straight segment of the proximal tubule; this consisted of varying degrees of cytoplasmic vacuolation, due to dilatation of both smooth and rough endoplasmic reticulum, and, at the highest dose tested, occasional individual cell necrosis and desquamation. Ultrastructural examination revealed additional dose-related abnormalities affecting the entire length of the proximal tubule, including increased lysosome production and the formation of cytosegresomes and myeloid bodies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7066186      PMCID: PMC2040750     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  15 in total

1.  Acute renal success. The unexpected logic of oliguria in acute renal failure.

Authors:  K Thurau; J W Boylan
Journal:  Am J Med       Date:  1976-09       Impact factor: 4.965

2.  Reversible suppression of allo-antibody production by cyclosporin A.

Authors:  S Denham; J M Styles; R K Barfoot; C J Dean
Journal:  Int Arch Allergy Appl Immunol       Date:  1980

3.  Timing of cyclosporin-A therapy for abrogation of HVG and GVH responses in rats.

Authors:  J R Markwick; J D Chambers; J R Hobbs; G D Pegrum
Journal:  Lancet       Date:  1979-11-17       Impact factor: 79.321

4.  Nephrotoxicity of cyclosporin A in liver and kidney transplant patients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Lancet       Date:  1981-02-28       Impact factor: 79.321

5.  Hepatic and renal function in rats receiving immunotherapeutic doses of cyclosporin A.

Authors:  P H Whiting; A W Thomson; I D Cameron; J G Simpson
Journal:  Br J Exp Pathol       Date:  1980-12

6.  Serum and urine N-acetyl-beta-D-glucosaminidase in diabetics on diagnosis and subsequent treatment, and stable insulin dependent diabetics.

Authors:  P H Whiting; I S Ross; L Borthwick
Journal:  Clin Chim Acta       Date:  1979-03-15       Impact factor: 3.786

7.  Immunosuppression with cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anaemia: preliminary studies.

Authors:  J Hows; R Harris; S Palmer; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1981-06       Impact factor: 6.998

8.  Cyclosporin A in cadaveric organ transplantation.

Authors:  R Y Calne; D J White; D B Evans; S Thiru; R G Henderson; D V Hamilton; K Rolles; P McMaster; T J Duffy; B R MacDougall; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-21

9.  Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation.

Authors:  R L Powles; H M Clink; D Spence; G Morgenstern; J G Watson; P J Selby; M Woods; A Barrett; B Jameson; J Sloane; S D Lawler; H E Kay; D Lawson; T J McElwain; P Alexander
Journal:  Lancet       Date:  1980-02-16       Impact factor: 79.321

10.  Studies on the immunosuppressive properties of cyclosporin a in rats receiving renal allografts.

Authors:  W P Homan; J W Fabre; K A Williams; P R Millard; P J Morris
Journal:  Transplantation       Date:  1980-05       Impact factor: 4.939

View more
  19 in total

1.  Potentiation of vascular smooth muscle cell activity by cyclosporin A.

Authors:  R Locher; R Huss; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Complications of cyclosporin therapy.

Authors:  B D Kahan; S M Flechner; M I Lorber; C Jensen; D Golden; C T Van Buren
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

3.  The toxic effects of combined administration of cyclosporin A and gentamicin.

Authors:  P H Whiting; J G Simpson; R J Davidson; A W Thomson
Journal:  Br J Exp Pathol       Date:  1982-10

4.  Cyclosporin therapy in vivo attenuates the response to vasodilators in the isolated perfused kidney of the rabbit.

Authors:  H S Cairns; L D Fairbanks; J Westwick; G H Neild
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

5.  Pathological changes in rats receiving cyclosporin A at immunotherapeutic dosage for 7 weeks.

Authors:  P H Whiting; J G Simpson; R J Davidson; A W Thomson
Journal:  Br J Exp Pathol       Date:  1983-08

6.  Cyclosporin A-induced nephrotoxicity in the rat: relationship to increased plasma renin activity.

Authors:  F T McAuley; J G Simpson; A W Thomson; P H Whiting
Journal:  Agents Actions       Date:  1987-06

7.  Renal injury induced by long-term administration of cyclosporin A to rats.

Authors:  T Bertani; N Perico; M Abbate; C Battaglia; G Remuzzi
Journal:  Am J Pathol       Date:  1987-06       Impact factor: 4.307

8.  Renal and hepatic function in rats treated with cyclosporin A in combination with gentamicin or cephalosporin antibiotics.

Authors:  P H Whiting; A W Thomson; J G Simpson
Journal:  Br J Exp Pathol       Date:  1983-12

9.  Thymic and lymphoid changes and serum immunoglobulin abnormalities in mice receiving cyclosporine.

Authors:  A Hattori; H W Kunz; T J Gill; H Shinozuka
Journal:  Am J Pathol       Date:  1987-07       Impact factor: 4.307

10.  Effects of cyclosporin A on mouse lymphoid tissues.

Authors:  O Kai; R M Franklin
Journal:  Br J Exp Pathol       Date:  1983-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.